Back | Next |
home / stock / sprb / sprb message board
Subject | By | Source | When |
---|---|---|---|
stock | pzottkpz | investorshub | 01/11/2023 5:16:09 PM |
know your pumpers | pzottkpz | investorshub | 01/11/2023 2:21:59 AM |
$SPRB Up a little more, today. | MiamiGent | investorshub | 01/11/2023 1:51:16 AM |
#FURU AHHA LOL https://twitter.com/furualerts/status/1612443799678078978 | TheFinalCD | investorshub | 01/10/2023 7:59:47 PM |
cmon man | pzottkpz | investorshub | 01/10/2023 3:04:36 PM |
day 3 pump and dump | pzottkpz | investorshub | 01/10/2023 9:10:23 AM |
$SPRB Closed today at $2.53 +$0.11 (+4.55%) | MiamiGent | investorshub | 01/10/2023 2:12:41 AM |
$SPRB Closed today at $2.53 +$0.11 (+4.55%) | MiamiGent | investorshub | 01/10/2023 2:12:40 AM |
what happened | pzottkpz | investorshub | 01/09/2023 10:25:05 PM |
bahahahahaha | pzottkpz | investorshub | 01/09/2023 4:02:34 PM |
$SPRB reached 2.85 +45 or +19% at the open | MiamiGent | investorshub | 01/09/2023 3:31:10 PM |
Nice. Thank you | subslover | investorshub | 01/09/2023 2:18:43 PM |
On January 9, 2023, the Company issued a | TheFinalCD | investorshub | 01/09/2023 1:42:59 PM |
https://ih.advfn.com/stock-market/NASDAQ/spruce-biosciences-$SPRB/stock-news/8993 | TheFinalCD | investorshub | 01/09/2023 1:41:35 PM |
$SPRB 2.20-2.85 quick | TheFinalCD | investorshub | 01/09/2023 1:38:43 PM |
Futures up .33% | MiamiGent | investorshub | 01/09/2023 12:00:21 PM |
would a | pzottkpz | investorshub | 01/09/2023 11:31:52 AM |
someone | pzottkpz | investorshub | 01/08/2023 10:59:31 PM |
$SPRB Spruce Biosciences Inc. ($SPRB) Is Worth Accumulating | MiamiGent | investorshub | 01/08/2023 10:25:39 PM |
I hope | pzottkpz | investorshub | 01/08/2023 6:38:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...